{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:55:22Z","timestamp":1763564122914,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":315,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2015\/03756-4"],"award-info":[{"award-number":["2015\/03756-4"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["305068\/2014-8"],"award-info":[{"award-number":["305068\/2014-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2020]]},"DOI":"10.6061\/clinics\/2020\/e1870","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T17:05:32Z","timestamp":1604941532000},"page":"e1870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8511-5688","authenticated-orcid":false,"given":"Andrea Yukie","family":"Shimabuco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-5906","authenticated-orcid":false,"given":"Ana Cristina de","family":"Medeiros-Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-601X","authenticated-orcid":false,"given":"Renata","family":"Miossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3547-5674","authenticated-orcid":false,"given":"Karina Rossi","family":"Bonfiglioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5766-6802","authenticated-orcid":false,"given":"Julio Cesar Bertacini de","family":"Moraes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2024-4961","authenticated-orcid":false,"given":"Celio Roberto","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9843-6686","authenticated-orcid":false,"given":"Percival Degrava","family":"Sampaio-Barros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3306-9699","authenticated-orcid":false,"given":"Claudia","family":"Goldenstein-Schainberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1771-6174","authenticated-orcid":false,"given":"Fernando Henrique Carlos de","family":"Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3192-7365","authenticated-orcid":false,"given":"Leandro Lara do","family":"Prado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-129X","authenticated-orcid":false,"given":"Michele Remi\u00e3o","family":"Ugolini-Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8801-405X","authenticated-orcid":false,"given":"Emily Figueiredo Vieira Neves","family":"Yuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-4681","authenticated-orcid":false,"given":"Eloisa","family":"Bonfa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9720-0719","authenticated-orcid":false,"given":"Carla Gon\u00e7alves Schahin","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.6061\/clinics\/2020\/e1870_bib1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"sup1","key":"10.6061\/clinics\/2020\/e1870_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.6061\/clinics\/2020\/e1870_bib3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"author":"Minist\u00e9rio da Sa\u00fade","key":"10.6061\/clinics\/2020\/e1870_bib4"},{"key":"10.6061\/clinics\/2020\/e1870_bib5","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3899\/jrheum.120165","article-title":"Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety","volume":"39","author":"Bombardier","year":"2012","journal-title":"J Rheumatol"},{"issue":"5","key":"10.6061\/clinics\/2020\/e1870_bib6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"10","key":"10.6061\/clinics\/2020\/e1870_bib7","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3899\/jrheum.090150","article-title":"Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial","volume":"36","author":"Park","year":"2009","journal-title":"J Rheumatol"},{"issue":"6","key":"10.6061\/clinics\/2020\/e1870_bib8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.23705","article-title":"Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy","volume":"59","author":"Chen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.6061\/clinics\/2020\/e1870_bib9","article-title":"Incidence of Infectious Adverse Events in Patients with Rheumatoid Arthritis and Spondyloarthritis on Biologic Drugs-Data From the Brazilian Registry for Biologics Monitoring","author":"Cecconi","year":"2018","journal-title":"J Clin Rheumatol"},{"issue":"8","key":"10.6061\/clinics\/2020\/e1870_bib10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.5588\/ijtld.13.0755","article-title":"LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area","volume":"18","author":"Bonfiglioli","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10.6061\/clinics\/2020\/e1870_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.rbr.2014.06.006","article-title":"Seguran\u00e7a do uso de terapias biol\u00f3gicas para o tratamento de artrite reumatoide e espondiloartrites [Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritis]","volume":"55","author":"Mota","year":"2015","journal-title":"Rev Bras Reumatol"},{"year":"2011","series-title":"Guidelines for the control of tuberculosis in Brazil, 2011. Minist\u00e9rio da Sa\u00fade, Bras\u00edlia, Brazil","author":"Minist\u00e9rio da Sa\u00fade","key":"10.6061\/clinics\/2020\/e1870_bib12"},{"year":"2018","series-title":"Protocol for Latent Tuberculosis Infection surveillance in Brazil. Minist\u00e9rio da Sa\u00fade, Bras\u00edlia, Brazil","author":"Minist\u00e9rio da Sa\u00fade","key":"10.6061\/clinics\/2020\/e1870_bib13"},{"issue":"4","key":"10.6061\/clinics\/2020\/e1870_bib14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.rbr.2015.01.006","volume":"55","author":"da Mota","year":"2015","journal-title":"Rev bras reumatol"},{"issue":"2","key":"10.6061\/clinics\/2020\/e1870_bib15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/1756-185X.13376","article-title":"Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India","volume":"22","author":"Shobha","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.6061\/clinics\/2020\/e1870_bib16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/annrheumdis-2019-eular.4624","article-title":"SAT0123 Risk for tuberculosis during treatment with biological therapy: is it time for reviewing screening protocol? - Results from Brazilian Registry of Biological Therapies in Rheumatic Diseases","volume":"78","author":"Ribeiro","year":"2019","journal-title":"(BIOBADABRASIL) Annals of the Rheumatic Diseases"},{"issue":"7","key":"10.6061\/clinics\/2020\/e1870_bib17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1590\/0074-02760150235","article-title":"Incidence of active mycobacterial infections in Brazilian patients with chronic inflammatory arthritis and negative evaluation for latent tuberculosis infection at baseline\u2013a longitudinal analysis after using TNFa blockers","volume":"110","author":"Gomes","year":"2015","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"9","key":"10.6061\/clinics\/2020\/e1870_bib18","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s10067-017-3916-y","article-title":"Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol","volume":"37","author":"Soare","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.6061\/clinics\/2020\/e1870_bib19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and tuberculosis risks","volume":"8","author":"Wallis","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.6061\/clinics\/2020\/e1870_bib20","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s10067-017-3714-6","article-title":"Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents","volume":"36","author":"Garziera","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.6061\/clinics\/2020\/e1870_bib21","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3899\/jrheum.110373","article-title":"Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers","volume":"38","author":"Kim","year":"2011","journal-title":"J Rheumatol"},{"issue":"2","key":"10.6061\/clinics\/2020\/e1870_bib22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/acr.21788","article-title":"Comprehensive tuberculosis screening program in patients with inflammatory arthritis treated with golimumab, a human anti-tumor necrosis factor antibody, in phase III clinical trials","volume":"65","author":"Hsia","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.6061\/clinics\/2020\/e1870_bib23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3899\/jrheum.150177","article-title":"Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-\u03b1 Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence","volume":"43","author":"Kisacik","year":"2016","journal-title":"J Rheumatol"},{"key":"10.6061\/clinics\/2020\/e1870_bib24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/ciu796","article-title":"Prevention of anti-tumor necrosis factor-associated tuberculosis: a 10-year longitudinal cohort study","volume":"60","author":"Mu\u00e3oz","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.6061\/clinics\/2020\/e1870_bib25","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.semarthrit.2012.07.001","article-title":"Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in Korean patients with rheumatic diseases","volume":"42","author":"Kim","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.6061\/clinics\/2020\/e1870_bib26","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/1756-185X.13261","volume":"21","author":"Malaviya","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.6061\/clinics\/2020\/e1870_bib27","article-title":"Diagnosis of latent tuberculosis in rheumatoid arthritis (RA)patients:tuberculintest(PPD)assessment","author":"Laurindo","year":"2004","journal-title":"EULAR"},{"issue":"Suppl 2","key":"10.6061\/clinics\/2020\/e1870_bib28","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"4","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.6061\/clinics\/2020\/e1870_bib29","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1136\/annrheumdis-2011-200408","article-title":"Influence of replacing tuberculin skin test with ex vivo interferon \u03b3 release assays on decision to administer prophylactic tuberculosis antibiotics before anti-TNF therapy","volume":"71","author":"Mariette","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.6061\/clinics\/2020\/e1870_bib30","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/art.34382","article-title":"Interferon-\u03b3 release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis","volume":"64","author":"Hsia","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.6061\/clinics\/2020\/e1870_bib31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/rheumatology\/key364","article-title":"Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region","volume":"58","author":"Wang","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.6061\/clinics\/2020\/e1870_bib32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/1756-185X.12530","article-title":"Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden","volume":"18","author":"Jung","year":"2015","journal-title":"Int J Rheum Dis"},{"issue":"Suppl 2","key":"10.6061\/clinics\/2020\/e1870_bib33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.rbr.2017.05.003","article-title":"Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitora\u00e7\u00e3o de Terapias Biol\u00f3gicas - BiobadaBrasil)","volume":"57","author":"Yonekura","year":"2017","journal-title":"Rev Bras Reumatol Engl Ed"},{"issue":"5","key":"10.6061\/clinics\/2020\/e1870_bib34","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s10067-019-04866-x","article-title":"Incidence of tuberculosis in patients receiving anti-TNF therapy for rheumatic diseases: a systematic review","volume":"39","author":"Sartori","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.6061\/clinics\/2020\/e1870_bib35","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12879-016-1550-y","article-title":"Initiation and completion rates for latent tuberculosis infection treatment: a systematic review","volume":"16","author":"Sandgren","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.6061\/clinics\/2020\/e1870_bib36","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1183\/09031936.00079310","article-title":"Treatment of latent infection with Mycobacterium tuberculosis: update 2010","volume":"37","author":"Leung","year":"2011","journal-title":"Eur Respir J"},{"issue":"5","key":"10.6061\/clinics\/2020\/e1870_bib37","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"Gomez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.6061\/clinics\/2020\/e1870_bib38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3899\/jrheum.140102","article-title":"Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"issue":"5","key":"10.6061\/clinics\/2020\/e1870_bib39","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"issue":"2","key":"10.6061\/clinics\/2020\/e1870_bib40","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry","volume":"69","author":"Greenberg","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.6061\/clinics\/2020\/e1870_bib41","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/07853890.2014.941919","article-title":"Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials","volume":"46","author":"Lorenzetti","year":"2014","journal-title":"Ann Med"},{"issue":"Suppl 2","key":"10.6061\/clinics\/2020\/e1870_bib42","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/annrheumdis-2013-203348","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012","author":"Furst","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.6061\/clinics\/2020\/e1870_bib43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3899\/jrheum.140101","article-title":"Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations","volume":"91","author":"Iannone","year":"2014","journal-title":"J Rheumatol Suppl"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S180759322200360X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S180759322200360X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:54:06Z","timestamp":1761720846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S180759322200360X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":43,"alternative-id":["S180759322200360X"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2020\/e1870","relation":{},"ISSN":["1807-5932"],"issn-type":[{"type":"print","value":"1807-5932"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2020\/e1870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e1870"}}